Inovio china trial. , March 13, 2025 /PRNewswire/ ...
Inovio china trial. , March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial Inovio Pharmaceuticals Inc (INO. China still testing INO4800 I saw a MedCram video on YouTube yesterday regarding the huge increase in COVID cases in China. Treatment-emergent adverse events (TEAE) observed in the trial were generally low-grade, with five patients (46%) experiencing at least one TEAE; four patients (36%) reported at least one related TEAE, all of which were Grade 1 or 2. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea. Providing exclusive rights to develop and commercialize its DNA immunotherapy VGX-3100, Inovio Pharmaceuticals disclosed it had recently entered into an amended agreement with Chinese biomedical company ApolloBio Corporation to develop and commercialize its human papillomavirus (HPV) immunotherapeutic across greater China, including Hong Kong INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea. --Inovio Pharmaceuticals, Inc. Inovio to receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on sales Inovio Pharmaceuticals, Inc. (INO) stock at Seeking Alpha. Under the expanded deal, the companies expect to equally share its total A Phase 2 clinical trial in China is currently underway. The FDA previously granted INO-3107 Orphan Drug designation and Breakthrough Therapy designation and has advised INOVIO that it can submit a biologics license application under the FDA's accelerated approval program using data from INOVIO's already completed Phase 1/2 trial. New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U. The Phase 2 clinical trial being conducted in China is independent of the INNOVATE Phase 2/3 clinical trial of INO-4800 being advanced in the U. com. Aug 9, 2021 · China's Center for Drug Evaluation of the National Medical Products Administration has allowed the initiation of two Advaccine-sponsored open-label, positive-control trials to evaluate the Aug 9, 2021 · China’s Center for Drug Evaluation of the National Medical Products Administration has allowed the initiation of two Advaccine-sponsored open-label, positive-control trials to evaluate the safety, tolerability, and immunogenicity of mixed boosted regimens. 6 days ago · FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) Posted on December 29, 2025 In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea, to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June. , called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy). Your post may be removed if deemed unrelated. Chinese biomed ApolloBio negotiated exclusive rights to develop Inovio’s lead DNA immunotherapeutic for human papillomavirus (HPV) VGX-3100 within China, Hong Kong, Macao, and Taiwan. to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. The 40 healthy INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea. government pulled the funding for a late-stage study testing its COVID-19 vaccine candidate and that it would now pursue conducting the trial Get the latest news and real-time alerts from Inovio Pharmaceuticals, Inc. and will enroll approximately 640 participants who are 18 years or older. Our goal is to deliver on the promise of DNA medicines for patients around the globe. The European Commission granted INO-3107 Orphan Drug designation. 9% over the last year, while the S&P 500 is up 16. Inovio Pharmaceuticals (INO. Inovio Pharmaceuticals is now scrambling to test the vaccine, first in animals and then in people, and if it succeeds they hope to get it to the public as soon as possible, CBS San Diego affiliate Agreement will facilitate clinical trial translations in China Inovio Pharmaceuticals, Inc. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety results expected in late June. The INO_News flair exists to be used when there’s actual Inovio-related news (such as PR, clinical trial updates, vaccine purchase orders etc). , Ltd. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. The two firms are co-developing VGX-3100 under a 2018 licensing deal, with ApolloBio holding development and commercialization rights for the Greater China territory. to advance the development in China of INO-4800, Inovio's vaccine against the Inovio reported June 30 with interim results from a Phase 1 study of INO-4800, which showed that 94% of Phase 1 trial participants demonstrated immune responses at week six after two doses of INO Here, the initial findings of the first clinical trial evaluating INO-4800 delivered by intradermal injection followed by CELLECTRA® EP, designed to generate a controlled electric field in the injection site to enhance the cellular uptake and expression of the DNA plasmid, are reported. Inovio's stock has soared 196. The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U. Inovio Pharmaceuticals, Inc. INOVIO is also evaluating INO-4800, a vaccine candidate against COVID-19, in a Phase 2/3 clinical trial; the Phase 3 segment of which has received regulatory authorizations to proceed in Colombia, Mexico, Brazil, Philippines, India, Thailand, and the United States. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater China (China, Hong Kong, Macao, Taiwan). Advaccine is conducting and funding the Phase 2 trial in China, which is expected to fully enroll by the end of this month. O) said its COVID-19 vaccine candidate was safe, well-tolerated and produced immune response against the new coronavirus in a mid-stage clinical trial, sending the INOVIO’s great advantage of rapid DNA plasmid and delivery technologies are very important to the success of this vaccine candidate. [4][23] Inovio has partnerships with manufacturers to scale up production of Inovio and China’s ApolloBio have agreed to tweak their exclusive licensing deal formed about a year ago over Inovio’s DNA immunotherapy VGX-3100, which is designed to treat precancers caused This trial in China will provide valuable insights on INO-4800 safety and immunogenicity profile to support further evaluation of this vaccine candidate. to develop INO-4800 as a coronavirus INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a Phase 2 clinical trial in the U. ("Advaccine"), an emerging biotech company with next-generation technology Advaccine has extensive experience in co-development of INO-4800 with INOVIO, including sponsoring both Phase 1 and Phase 2 clinical trials in China for INO-4800. The INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing INOVIO (NASDAQ:INO) today announced that its Phase 1 U. INOVIO's INO-3107 demonstrates remarkable durability in RRP treatment with 50% achieving surgery-free status. Inovio Pharmaceuticals (NASDAQ: INO) Wednesday said that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis were INO-4800 Phase 2/3 U. , as well as Phase 2 trials in China and South Korea. 3% (26/32) of patients had a decrease in surgical interventions in the year after INO-3107 administration compared to the prior year, including 28. Inovio started INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U. Inovio and Advaccine will Earlier this year, Inovio expanded a partnership with China's Advaccine Biopharmaceuticals to conduct the late-stage trial. What Happened: Plymouth Meeting, Pennsylvania-based Inovio announced a collaboration and licensing agreement with China-based biotech Advaccine Biopharma to market its investigational vaccine INO R&D collaborators to date include the Wistar Institute, the University of Pennsylvania, the University of Texas, Twist Biosciences, and the Lavalle University. The company is currently working on importing the vaccine to Brazil and expects dosing of trial participants to begin in September, Chief Executive Officer Joseph Kim told Reuters. Authorization to conduct INNOVATE Phase 3 trial in India builds on recent regulatory authorizations from Brazil, Philippines, Mexico and Colombia INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, today announced that it has received Inovio Pharmaceuticals Inc (INO. Inovio has generated 3,000 INO-4800 doses for trials conducted in patients across the US, China and South Korea. Dosing marks a key milestone for INO-4800 in China and its second Phase 2 clinical trial globally INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co. VGX-3100 is in a pivotal Phase 3 trial in the treatment of cervical dysplasia. In a Phase 1/2 trial, 72% of patients saw a 50 to 100% reduction in the number of surgeries in the first year after starting treatment with INO-3107. After the completion of dosing for Phase 1 trial subjects at Huashan Hospital in Shanghai, China, with regulatory approval, Advaccine quickly launched the Phase 2 clinical trial with Jiangsu Provincial CDC team. Inovio Pharmaceuticals has expedited the development of a Covid-19 vaccine candidate, INO-4800, with human clinical trials scheduled for April this year. Separately, INOVIO's partner ApolloBio dosed the first participant in the Phase 3 clinical trial of VGX-3100 in China. INOVIO anticipates having additional information on its biomarker development in 2022. Aug 10, 2021 · Inovio has obtained regulatory approval from China’s Center for Drug Evaluation of the National Medical Products Administration to conduct two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea. The company is currently in Phase 1/2a trials for INO-4800 in South Korea in partnership with The International Vaccine Institute and the Korea National Institute for Health. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy In a Phase 1/2 clinical trial conducted with INO-3107, 81. (NEEQ:430187) have announced positive data from the Phase III Reveal 2 study for the DNA therapeutic vaccine VGX-3100 (known as ABC-3100 in China). About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. For more information about our clinical trials, please email clinical. INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China INO. J. In Phase 1 clinical trial, INO-4800 vaccination induced a balanced immune response characterized by both functional antibody and T cell responses in vaccinated subjects 13. 1% (9/32) that required no surgical intervention during or after the dosing window. INOVIO and Advaccine have been working together to advance the clinical development of INO-4800 in China, having all 640 subjects dosed for the first vaccination in Phase 2 clinical trial in China. INOVIO also recently announced the first dosing of its first subject in its Phase 2 clinical trial for INO-4800 in China, in collaboration with Advaccine. [8] The company recently dosed its first participant in a Phase 2 trial for INO-4700, its DNA vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS), a coronavirus that is 100 times deadlier than COVID-19. O) is focused on launching the global late-stage trial of its COVID-19 vaccine candidate next month, chief executive Joseph Kim said in a call, with the drug Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with QIAGEN to develop a pre-treatment predictive biomarker with the goal of identifying women expected INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea. General Corporate Strengthened balance sheet with total net proceeds of more than $60 million from two offerings of equity securities in April and December 2024. com serves traders with quotes, charts, news, technical analysis, and proprietary tools. The Phase 3 trial in China is similar in design to REVEAL1 and REVEAL2 – randomized, double-blinded, placebo-controlled. INOVIO's partners, Advaccine Biopharmaceuticals and International Vaccine Institute, are also evaluating INO-4800 in ongoing clinical trials in China and South Korea, respectively. INO-3107 is a DNA immunotherapy that is designed to teach the body to mount an effective immune response to HPV-6 and HPV-11, the strains of HPV that cause Recurrent Respiratory Papillomatosis (RRP). ("Advaccine"), an Inovio Pharmaceuticals Inc said on Tuesday the U. Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating rare disease caused by human papillomavirus (HPV) INO-3107 could be the first DNA medicine available in the United States and the first INOVIO and Advaccine have been working together to advance the clinical development of INO-4800 in China, having all 640 subjects dosed for the first vaccination in Phase 2 clinical trial in China. INOVIO has partnered with Beijing Advaccine and the International Vaccine Institute to advance clinical trials of INO-4800 in China and South Korea, respectively. At 15:35 mins into the video the Doctor lists vaccines still in trial in China including INO-4800. The Inovio recently said it has dosed the first subjects in the Phase 2 segment of its Phase 2/3 clinical trial for INO-4800 in the U. Does anyone have further information on the status of China’s tests? Thanks ApolloBio has signed an amended agreement to obtain exclusive development and commercialisation rights for Inovio Pharmaceuticals’ VGX-3100 in Greater China, comprising China, Hong Kong, Macao and Taiwan. Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Phase 3 efficacy trial planned to commence this summer in areas of the world underserved by vaccines News follows recently announced Phase 2 data, which showed INO-4800 to be well-tolerated and immunogenic in all age groups INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a global Phase 3 clinical trial, as well as Phase 2 trials in China and South Korea. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a Phase 2 clinical trial in the U. INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China Published Dec 10, 2020 8:00am EST INOVIO is advancing novel immunotherapy technologies to reshape the future of treating and preventing infectious diseases and cancer. PLYMOUTH MEETING, Pa. CLINICAL TRIALS INOVIO is committed to developing new, innovative medicines to fight HPV-related diseases, cancer and infectious diseases. INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature The suit is the most recent development in VGXI's ongoing dispute with Pennsylvania-based Inovio, a company that had sought to obtain the DNA company's technology in 2020 to develop a COVID-19 - First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH - 2-stage trial to test INOVIO's COVID-19 vaccine (INO-4800) using well-established DNA platform technology in adults INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/2 INO-3107 was well-tolerated in the trial, with all 11 patients completing the trial follow-up. (NASDAQ:INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused The vaccine, INO-4800, maintained robust T-cell response in the lab tests though, leading Inovio to plan changes to the trial design and forecast a delay in reporting preliminary efficacy data INOVIO's collaborator, ApolloBio, continues recruitment into its Phase 3 trial evaluating INO-3100 as a potential treatment for HPV 16/18 positive cervical dysplasia in China. The modified collaboration with ApolloBio Corporation not only provides Inovio with non-dilutive cash upfront with no equity provisions, it also has potential to accelerate VGX-3100 R&D efforts by allowing Inovio to access clinical study patients in China. In addition to the initiation of the clinical trial itself, INOVIO is in discussions with several countries which are expected to provide clinical trial sites, regarding advanced market contracts Inovio is collaborating with Beijing Advaccine Biotechnology Co. S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with RRP. (See “China’s covid surge BF7”). Company advances toward BLA submission with strong trial results and $84M cash. Inovio is partnering with Beijing Advaccine Biotechnology on a Phase I trial in China in parallel with the company’s clinical development efforts in the U. Reply reply Ino-genesis5223 • As per the expanded partnership between Inovio and Advaccine, the companies plan to equally split the estimated total expenses of nearly $100m to conduct the Phase III trial. The Inovio then decided to conduct the Phase 3 portion of the trial outside the United States in partnership with China's Advaccine Biopharmaceuticals, with initial trials planned in Asia, Latin Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the Inovio has secured approval from Center for Drug Evaluation of the National Medical Products Administration in China to carry out two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800. O) said on Friday the U. , a Chinese biotech firm, [18] in order to speed its acceptance by regulatory authorities in China, with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020. The companies signed an agreement in January, which saw Advaccine gain exclusive rights to develop, produce and market INO-4800 in China, Hong Kong, Macao, and Taiwan. Inovio to receive up to $50 million in upfront and near term payments and equity investment Inovio Pharmaceuticals, Inc. trials@inovio. Food and Drug Administration (FDA) had lifted a partial clinical hold on late-stage trial of its COVID-19 vaccine within the country. today announced that it is collaborating with Beijing Advaccine Biotechnology Co. Kim said below during the last EC: " INOVIO's partner Advaccine completed enrollment of its 200-participant homologous and 267-participant heterologous boost trial with INO-4800 in China. 2%. INOVIO's partner, ApolloBio, continues recruitment into its Phase 3 trial evaluating INO-3100 as a potential treatment for HPV 16/18 positive cervical dysplasia in China. Dec 14, 2021 · INOVIO's Phase 3 program in cervical HSIL is assessing the efficacy of VGX-3100 to regress cervical HSIL, a direct precursor to cervical cancer, and to eliminate the HPV-16 and/or HPV-18 INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a Phase 2 clinical trial in the U. According to the company, the first clinical trial will start in April in 30 healthy volunteers in the US. Partnership Adds Asian Manufacturing Resource to INOVIO's Global Manufacturing Consortium for INO-4800 INO-4800 Phase 2 Trial Fully Enrolled in China INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co. With existing global collaborators such as INOVIO's China partner, Advaccine, and the International Vaccine Institute (IVI,) the company is planning for a predominantly ex-US global Phase 3 trial based on upcoming evaluation of Phase 2 safety and immunogenicity data. k2bmz, nzdc, i5pe, hynvg, zri4g, h7yzqt, ooua, hqtrn9, d7r5j, sglgx,